TMEM44 Inhibitors
TMEM44 Inhibitors encompass a group of chemical compounds that indirectly suppress the functional activity of TMEM44 through various cellular signaling pathways. Compounds such as Rapamycin, LY 294002, Wortmannin, and Triciribine act upon the PI3K/AKT/mTOR axis, which is integral to cell growth and proliferation, processes in which TMEM44 plays a role. Through the inhibition of kinases like mTOR and AKT, these inhibitors disrupt downstream signaling that would otherwise support TMEM44's function, leading to its diminished activity. Likewise, PD 98059, SP600125, SB 203580, and U0126 target members of the MAPK signaling cascade, such as ERK, JNK, and p38, whose activities are crucial for cell cycle progression and survival. By impeding these kinases, the inhibitors indirectly hinder TMEM44's participation in these pathways. Furthermore, Dasatinib's inhibition of BCR-ABL and Src family kinases, and Palbociclib's targeted blockage of CDK4/6, further reduce TMEM44's functional involvement by weakening the signaling required for cell cycle control and proliferation, where TMEM44 is potentially active.
Additionally, specific inhibitors like Gö 6983, which targets PKC isoforms, and Leflunomide, which impedes pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase, contribute to the reduction of TMEM44's functional activity. By disrupting PKC signaling, Gö 6983 indirectly decreases TMEM44's role in cell survival pathways, while Leflunomide's impact on nucleotide biosynthesis attenuates cell proliferation, further diminishing TMEM44's functional relevance in these biological processes. Collectively, these TMEM44 Inhibitors, through their targeted and indirect actions, serve as essential tools for understanding and manipulating the cellular functions in which TMEM44 is implicated, without directly altering the protein's expression or activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits the mechanistic target of rapamycin (mTOR), a kinase involved in cell growth and proliferation. As TMEM44 is associated with these cellular processes, its function is diminished by mTOR pathway inhibition. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an inhibitor of AKT, a serine/threonine-specific protein kinase. AKT inhibition can decrease cell survival and growth signals that TMEM44 may be part of, leading to indirect inhibition of TMEM44's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a selective inhibitor of PI3K, which disrupts the PI3K/AKT/mTOR pathway. As TMEM44 function is linked to cell proliferation, which is regulated by this pathway, inhibition of PI3K indirectly leads to the diminished function of TMEM44. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which blocks the MAPK/ERK pathway. Since ERK signaling can regulate cell cycle progression where TMEM44 is potentially involved, its function is indirectly diminished through MEK inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathway. By inhibiting JNK, this compound indirectly reduces the activity of downstream proteins involved in cell growth, potentially leading to reduced functional activity of TMEM44. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can lead to decreased cell proliferation and survival, thereby indirectly diminishing the functional activity of TMEM44 in these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By blocking PI3K, it disrupts the AKT pathway and indirectly diminishes the functional activity of TMEM44 associated with cell proliferation and survival pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö 6983 is a pan-PKC inhibitor that can inhibit protein kinase C (PKC) isoforms. Since PKC is involved in cell survival and proliferation, inhibition of PKC could indirectly decrease the functional activity of TMEM44. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases. By inhibiting these kinases, Dasatinib may interfere with signaling pathways that regulate cell proliferation, indirectly reducing TMEM44 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and consequently inhibits the ERK pathway. Since TMEM44 is implicated in cell cycle progression, inhibition of this pathway can lead to a decrease in TMEM44's functional involvement in these processes. | ||||||